These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Kim Chiaw P; Eckford PD; Bear CE Essays Biochem; 2011 Sep; 50(1):233-48. PubMed ID: 21967060 [TBL] [Abstract][Full Text] [Related]
29. Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222. Singh AK; Fan Y; Balut C; Alani S; Manelli AM; Swensen AM; Jia Y; Neelands TR; Vortherms TA; Liu B; Searle XB; Wang X; Gao W; Hwang TC; Ren HY; Cyr D; Kym PR; Conrath K; Tse C J Pharmacol Exp Ther; 2020 Jan; 372(1):107-118. PubMed ID: 31732698 [TBL] [Abstract][Full Text] [Related]
30. Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines. Park J; Khloya P; Seo Y; Kumar S; Lee HK; Jeon DK; Jo S; Sharma PK; Namkung W PLoS One; 2016; 11(2):e0149131. PubMed ID: 26863533 [TBL] [Abstract][Full Text] [Related]
31. Fluorinated ΔF508-CFTR correctors and potentiators for PET imaging. Davison HR; Solano DM; Phuan PW; Verkman AS; Kurth MJ Bioorg Med Chem Lett; 2012 Feb; 22(4):1602-5. PubMed ID: 22281185 [TBL] [Abstract][Full Text] [Related]
32. A defective flexible loop contributes to the processing and gating defects of the predominant cystic fibrosis-causing mutation. Chen X; Zhu S; Zhenin M; Xu W; Bose SJ; Wong MP; Leung GPH; Senderowitz H; Chen JH FASEB J; 2019 Apr; 33(4):5126-5142. PubMed ID: 30668920 [TBL] [Abstract][Full Text] [Related]
33. Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis. Scanio MJC; Searle XB; Liu B; Koenig JR; Altenbach RJ; Gfesser GA; Bogdan A; Greszler S; Zhao G; Singh A; Fan Y; Swensen AM; Vortherms T; Manelli A; Balut C; Gao W; Yong H; Schrimpf M; Tse C; Kym P; Wang X Bioorg Med Chem Lett; 2022 Sep; 72():128843. PubMed ID: 35688367 [TBL] [Abstract][Full Text] [Related]
34. Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Leier G; Bangel-Ruland N; Sobczak K; Knieper Y; Weber WM Cell Physiol Biochem; 2012; 29(5-6):775-90. PubMed ID: 22613978 [TBL] [Abstract][Full Text] [Related]
35. Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector. Pizzonero M; Akkari R; Bock X; Gosmini R; De Lemos E; Duthion B; Newsome G; Mai TT; Roques V; Jary H; Lefrancois JM; Cherel L; Quenehen V; Babel M; Merayo N; Bienvenu N; Mammoliti O; Coti G; Palisse A; Cowart M; Shrestha A; Greszler S; Van Der Plas S; Jansen K; Claes P; Jans M; Gees M; Borgonovi M; De Wilde G; Conrath K J Med Chem; 2024 Apr; 67(7):5216-5232. PubMed ID: 38527911 [TBL] [Abstract][Full Text] [Related]
36. Structure-activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects. Csanády L; Töröcsik B J Gen Physiol; 2014 Oct; 144(4):321-36. PubMed ID: 25267914 [TBL] [Abstract][Full Text] [Related]
37. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and Structure-activity Relationship of Aminoarylthiazole Derivatives as Potential Potentiators of the Chloride Transport Defect in Cystic Fibrosis. Liessi N; Pesce E; Salis A; Damonte G; Tasso B; Cichero E; Pedemonte N; Millo E Med Chem; 2021; 17(6):646-657. PubMed ID: 32141420 [TBL] [Abstract][Full Text] [Related]
39. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis. Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]